MLYS Mineralys Therapeutics, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Business section lacks substantive description of core operations or products
• • Reliance on 2026 Proxy Statement for key corporate governance and executive compensation details
• • No disclosure of new products, services, strategic shifts, or geographic expansions this year
• • References Ernst & Young LLP as principal independent auditor for 2026 financial statements
• • Unusual focus on compliance codes and proxy statement incorporation, minimal direct business narrative

Risk Factors

• • Regulatory risk: FDA review pending for lorundrostat NDA submitted December 22, 2025, with no prior approvals or revenue
• • Macroeconomic risk: Global economic volatility and geopolitical conflicts (Ukraine, Israel, Venezuela) may restrict capital availability for operations
• • Supply chain risk: Dependency on third-party CMOs for cGMP-compliant manufacturing scale-up of lorundrostat, potential delays and cost increases
• • Competitive risk: Market acceptance risk due to potential competing products and alternative therapies affecting lorundrostat launch prospects
• • Financial risk: Accumulated deficit $457.2M with net losses $154.7M in 2025; need substantial capital raises risking dilution or restrictive debt covenants

Management Discussion & Analysis

• • No revenue; net loss $154.7M in 2025 vs $177.8M in 2024, improvement of $23.1M
• • R&D expenses $132.0M in 2025 vs $168.6M in 2024, a 21.7% decrease; G&A expenses $38.6M vs $23.8M, a 62.0% increase
• • No segments disclosed; entire focus on lorundrostat development and clinical trials
• • Cash, cash equivalents, and investments $656.6M at year-end 2025; raised $269.6M in Sept 2025, $188.7M in Mar 2025, and $139.6M via ATM offering through Mar 2026
• • Management expects cash to fund operations for at least 12 months; key risk is timing and success of regulatory approval and clinical trial outcomes

What are the latest MLYS SEC filings in 2026?

Mineralys Therapeutics, Inc. (MLYS) has filed a 10-K annual report on March 12, 2026, a 10-Q quarterly report on May 6, 2026, an 8-K current report on June 3, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did MLYS file its most recent 10-K annual report?

Mineralys Therapeutics, Inc. (MLYS) filed its most recent 10-K annual report on March 12, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view MLYS 10-Q quarterly reports?

Mineralys Therapeutics, Inc. (MLYS)'s most recent 10-Q quarterly report was filed on May 6, 2026. SignalX displays every MLYS 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has MLYS filed recently?

Mineralys Therapeutics, Inc. (MLYS)'s most recent 8-K was filed on June 3, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find MLYS insider trading activity (Form 4)?

SignalX aggregates every MLYS Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does MLYS file with the SEC?

Mineralys Therapeutics, Inc. (MLYS) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new MLYS filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Mineralys Therapeutics, Inc. (MLYS).

What is MLYS's SEC CIK number?

Mineralys Therapeutics, Inc. (MLYS)'s SEC CIK (Central Index Key) number is 1933414. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1933414 to look up all MLYS filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find MLYS return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Mineralys Therapeutics, Inc. (MLYS) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.